Takeda Pharmaceutical
TAK · NYSEPharmaceutical Preparations · Reports in JPY
Takeda Pharmaceutical reported revenue of JPY 4,582B in the fiscal year ended Mar 2025, up 7.5% from the year before. Operating income was JPY 343B, an operating margin of 7.5%, and net income was JPY 108B. Operating cash flow of JPY 1,057B less capital expenditure of JPY 201B left free cash flow of JPY 856B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | JPY 3,198B | JPY 3,569B | JPY 4,027B | JPY 4,264B | JPY 4,582B |
| Cost of revenue | JPY 994B | JPY 1,107B | JPY 1,244B | JPY 1,427B | JPY 1,580B |
| Gross profit | JPY 2,204B | JPY 2,462B | JPY 2,783B | JPY 2,837B | JPY 3,001B |
| Research & development | JPY 456B | JPY 526B | JPY 633B | JPY 730B | JPY 730B |
| Operating income | JPY 509B | JPY 461B | JPY 491B | JPY 214B | JPY 343B |
| Interest expense | JPY 131B | JPY 122B | JPY 117B | JPY 120B | JPY 137B |
| Pre-tax income | JPY 366B | JPY 303B | JPY 375B | JPY 52.8B | JPY 175B |
| Income tax | −JPY 9.9B | JPY 72.4B | JPY 58.1B | −JPY 91.4B | JPY 66.9B |
| Net income | JPY 376B | JPY 230B | JPY 317B | JPY 144B | JPY 108B |
Balance sheet
| Fiscal year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | JPY 966B | JPY 850B | JPY 534B | JPY 458B | JPY 385B |
| Receivables | JPY 783B | JPY 697B | JPY 649B | JPY 668B | JPY 709B |
| Inventory | JPY 754B | JPY 853B | JPY 986B | JPY 1,210B | JPY 1,217B |
| Current assets | JPY 2,713B | JPY 2,594B | JPY 2,398B | JPY 2,559B | JPY 2,521B |
| Net PP&E | JPY 1,454B | JPY 1,583B | JPY 1,691B | – | – |
| Goodwill | JPY 4,034B | JPY 4,408B | JPY 4,791B | JPY 5,410B | JPY 5,324B |
| Total assets | JPY 12,912B | JPY 13,178B | JPY 13,958B | JPY 15,109B | JPY 14,248B |
| Payables | JPY 344B | JPY 516B | JPY 649B | JPY 548B | JPY 476B |
| Current liabilities | JPY 1,773B | JPY 2,146B | JPY 2,482B | JPY 2,313B | JPY 2,507B |
| Total liabilities | JPY 7,735B | JPY 7,494B | JPY 7,603B | JPY 7,835B | JPY 7,312B |
| Shareholders' equity | JPY 5,173B | JPY 5,683B | JPY 6,354B | JPY 7,273B | JPY 6,935B |
Cash flow
| Fiscal year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating cash flow | JPY 1,011B | JPY 1,123B | JPY 977B | JPY 716B | JPY 1,057B |
| Capital expenditure | JPY 111B | JPY 123B | JPY 141B | JPY 175B | JPY 201B |
| Free cash flow | JPY 900B | JPY 1,000B | JPY 836B | JPY 541B | JPY 856B |
Key ratios
| Fiscal year | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 11.6% | 12.8% | 5.9% | 7.5% |
| Operating income growth (YoY) | – | −9.5% | 6.4% | −56.4% | 60.0% |
| Gross margin | 68.9% | 69.0% | 69.1% | 66.5% | 65.5% |
| Operating margin | 15.9% | 12.9% | 12.2% | 5.0% | 7.5% |
| Net margin | 11.8% | 6.4% | 7.9% | 3.4% | 2.4% |
| Return on equityBlank when equity is negative | 7.3% | 4.1% | 5.0% | 2.0% | 1.6% |
| ROCEEBIT ÷ (assets − current liabilities) | 4.6% | 4.2% | 4.3% | 1.7% | 2.9% |
| Free cash flow margin | 28.1% | 28.0% | 20.8% | 12.7% | 18.7% |
| Cash conversion (CFO ÷ net income) | 2.69x | 4.88x | 3.08x | 4.97x | 9.78x |
| Receivable days | 89 | 71 | 59 | 57 | 57 |
| Inventory days | 277 | 281 | 289 | 310 | 281 |
| Payable days | 126 | 170 | 190 | 140 | 110 |
| Interest cover | 3.89x | 3.76x | 4.19x | 1.79x | 2.49x |
| Current ratio | 1.53x | 1.21x | 0.97x | 1.11x | 1.01x |
Recent filings
More in Pharmaceutical Preparations
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.